Medication

UKI2S biotech company CellCentric, University of Cambridge spinout, has raised $26m to fund clinical testing of its first-in-class oncology drug candidate, CCS1477.

CellCentric focuses on treating prostate cancer, as well as multiple other cancers. Their new drug candidate addresses the large and increasing population of patients – upwards of 80,000 people each year -- who have tumours with inherent or acquired resistance to second generation anti-hormonal drugs.

“There is a large and growing population of late-stage prostate cancer patients who have inherent or acquired resistance to current second-line anti-androgen therapies,” commented Dr Will West, Chairman and CEO of CellCentric. “CCS1477 has shown promise in addressing this. It is positioned after or in combination with second generation anti-androgen drugs such as abiraterone, enzalutamide and apalutamide.”

We congratulate CellCentric on their advancement to treat cancer and save lives.

UKI2S
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.